NO20062118L - Inhibitor kontrastmidler - Google Patents

Inhibitor kontrastmidler

Info

Publication number
NO20062118L
NO20062118L NO20062118A NO20062118A NO20062118L NO 20062118 L NO20062118 L NO 20062118L NO 20062118 A NO20062118 A NO 20062118A NO 20062118 A NO20062118 A NO 20062118A NO 20062118 L NO20062118 L NO 20062118L
Authority
NO
Norway
Prior art keywords
contrast agents
inhibitor contrast
inhibitor
contrast
mmps
Prior art date
Application number
NO20062118A
Other languages
English (en)
Norwegian (no)
Inventor
Magne Solbakken
Alan Cuthbertson
Emma Bjurgert
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20062118L publication Critical patent/NO20062118L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
NO20062118A 2003-11-14 2006-05-11 Inhibitor kontrastmidler NO20062118L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents
PCT/GB2004/004792 WO2005049005A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents

Publications (1)

Publication Number Publication Date
NO20062118L true NO20062118L (no) 2006-05-11

Family

ID=29726529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062118A NO20062118L (no) 2003-11-14 2006-05-11 Inhibitor kontrastmidler

Country Status (16)

Country Link
US (1) US20070104644A1 (es)
EP (1) EP1682113B1 (es)
JP (1) JP5043438B2 (es)
KR (1) KR20060118479A (es)
CN (1) CN1901894A (es)
AT (1) ATE384519T1 (es)
AU (1) AU2004290950A1 (es)
BR (1) BRPI0416528A (es)
CA (1) CA2545267A1 (es)
DE (1) DE602004011553T2 (es)
ES (1) ES2299884T3 (es)
GB (1) GB0326546D0 (es)
MX (1) MXPA06005355A (es)
NO (1) NO20062118L (es)
RU (1) RU2006117298A (es)
WO (1) WO2005049005A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0520527D0 (en) * 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
ES2357861T3 (es) 2006-02-15 2011-05-03 Ge Healthcare As Agentes de contraste.
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
EP2597083A3 (en) * 2006-03-29 2014-09-17 Novartis AG Selective hydroxamate based MMP inhibitors
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
EP2091570A1 (en) * 2006-12-20 2009-08-26 GE Healthcare AS Contrast agents
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
JP5322527B2 (ja) * 2008-07-17 2013-10-23 浜松ホトニクス株式会社 アポトーシスの検出に適した化合物
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2010138720A2 (en) * 2009-05-27 2010-12-02 The Scripps Research Institute Compounds and methods for chelating metals in aqueous solutions
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース6−リン酸受容体を標的とする化合物
EP2493576A2 (en) 2009-10-29 2012-09-05 The Procter & Gamble Company Hair conditioning composition comprising cationic surfactant system, direct dye, and nonionic thickener
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
CN103980277B (zh) * 2014-05-27 2016-06-15 青岛大学 一种叶酸巯基化衍生物的制备方法
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714465A (en) * 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0895988B1 (en) * 1997-08-08 2002-05-22 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
DE69822839T2 (de) * 1997-08-08 2004-08-19 Pfizer Products Inc., Groton Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
DE69917124T2 (de) * 1998-04-10 2005-05-12 Pfizer Products Inc., Groton Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
TR200202163T2 (tr) * 1999-08-18 2002-11-21 Warner-Lambert Company Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
DE60114022T2 (de) * 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren
EP1592458A1 (en) * 2003-02-10 2005-11-09 GE Healthcare Limited Diagnostic imaging agents with mmp inhibitory activity

Also Published As

Publication number Publication date
JP5043438B2 (ja) 2012-10-10
DE602004011553T2 (de) 2009-03-26
ATE384519T1 (de) 2008-02-15
CN1901894A (zh) 2007-01-24
EP1682113B1 (en) 2008-01-23
JP2007511494A (ja) 2007-05-10
AU2004290950A1 (en) 2005-06-02
WO2005049005A1 (en) 2005-06-02
ES2299884T3 (es) 2008-06-01
BRPI0416528A (pt) 2007-01-09
RU2006117298A (ru) 2007-12-20
DE602004011553D1 (de) 2008-03-13
KR20060118479A (ko) 2006-11-23
EP1682113A1 (en) 2006-07-26
CA2545267A1 (en) 2005-06-02
MXPA06005355A (es) 2006-07-10
US20070104644A1 (en) 2007-05-10
GB0326546D0 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
NO20062118L (no) Inhibitor kontrastmidler
NO20072120L (no) Enzyme Inhibitor Imaging Agents
EP1547996A4 (en) DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES HAVING PRION PROTEIN ACCUMULATION AND METHOD OF MARKING
DE60308707D1 (de) Messkonstruktion für chirurgusche geräten
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
UY27972A1 (es) Derivados de hidantoína
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
DE60325567D1 (de) Matrix für die modifizierte freigabe von aktiven substanzen
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
DE602005003570D1 (de) Rohr- und universalkupplung für die zufuhr von zahnmedizinischen oder chirurgischen instrumenteen
ATE328865T1 (de) Okklusionszusammensetzung umfassend ein poly(2- cyanoacrylat)-monomer
DE60302995D1 (de) Blutdruckmessgerät
TW200617174A (en) Method of diagnosing lawsonia intracellularis
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
ATE519505T1 (de) Reaktive paramagnetische kontrastmittel für magnetresonanzbildgebung
NO20054049D0 (no) Fremgangsmate for diagnose og behandling.
WO2003095475A3 (en) Peptide compounds and their use as protease substrates
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
BRPI0515161A (pt) substratos enzimáticos derivados de fenoxazinona e seu uso como revelador na detecção de microorganismos com atividade de peptidase
DE60234821D1 (de) Messverfahren für vollblut
NZ597557A (en) Mycobacterial disease detection, treatment, and drug discovery
WO2001088533A3 (en) Lipid uptake assays
BR0317404A (pt) Variantes do fator xiia
ITMI20021976A1 (it) Procedimento e dispositivo per la diagnosi di uno smorzatore di pressioni.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application